Johnson & Johnson Archives -

Janssen J&J Johnson and Johnson pharmaceutical companies

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-bispecific-tecvayli-ahead-of-us-decision/

Market Access/ News/ News/ News/ Patients

NICE makes J&J’s Tremfya more accessible in England and Wales

Phil Taylor HEOR, Johnson & Johnson, NICE, psoriatic arthritis, Tremfya 0 Comment

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment

NICE makes J&J’s Tremfya more accessible in England and Wales

https://pharmaphorum.com/news/nice-makes-jjs-tremfya-more-accessible-in-england-and-wales/

News/ News/ R&D

Relief for GSK as RSV vaccine clears phase 3 test in adults

Phil Taylor Bavarian Nordic, GSK, Johnson & Johnson, Moderna, Pfizer, respiratory syncytial virus, vaccine 0 Comment

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the

Relief for GSK as RSV vaccine clears phase 3 test in adults

https://pharmaphorum.com/news/relief-for-gsk-as-rsv-vaccine-clears-phase-3-test-in-adults/

News/ News/ Oncology

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Phil Taylor ASCO 2022, BCMA, bispecific, elranatamab, Johnson & Johnson, multiple myeloma, Pfizer, teclistamab 0 Comment

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

https://pharmaphorum.com/news/asco22-jj-pfizer-trade-bcma-bispecific-data-in-myeloma/

News/ News/ Oncology

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Phil Taylor CAR-T therapies, Carvykti, EU, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval 0 Comment

Johnson & Johnson and Legend Biotech will arrive at next week’s ASCO congress with a new EU approval

J&J, Legend get EU nod for myeloma CAR-T Carvykti

https://pharmaphorum.com/news/jj-legend-get-eu-nod-for-myeloma-car-t-carvykti/

News

J&J names CEO of its consumer health unit ahead of spinout

Phil Taylor consumer health, Johnson & Johnson, senior management 0 Comment

Johnson & Johnson has appointed Thibaut Mongon as the chief executive of its consumer health division, which is

J&J names CEO of its consumer health unit ahead of spinout

https://pharmaphorum.com/news/jj-names-ceo-of-its-consumer-health-unit-ahead-of-spinout/

Market Access/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Saving lives doesn’t have to cost the Earth

mike.hammerton@pharmaphorum.com climate change, global warming, Jamie Phares, Janssen, Johnson & Johnson, pharma 0 Comment

Jamie Phares, managing director, The Janssen Pharmaceutical Companies of Johnson & Johnson in the Gulf Cooperation Council (GCC),

Saving lives doesn’t have to cost the Earth

https://pharmaphorum.com/market-access-2/environmental-impact-saving-lives-doesnt-have-to-cost-earth/

News/ News/ R&D

J&J ducks out of Bavarian Nordic vaccine partnerships

Phil Taylor Bavarian Nordic, hepatitis B, HPV, Janssen, Johnson & Johnson, partnering, vaccine 0 Comment

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its

J&J ducks out of Bavarian Nordic vaccine partnerships

https://pharmaphorum.com/news/jj-ducks-out-of-bavarian-nordic-vaccine-partnerships/

News/ News/ News/ Patients/ Sales and Marketing

J&J on the hook for $302m in pelvic mesh dispute

Phil Taylor Johnson & Johnson, liability, pelvic mesh 0 Comment

An appeals court in California has upheld a lower court ruling that ordered Johnson & Johnson to pay

J&J on the hook for $302m in pelvic mesh dispute

https://pharmaphorum.com/news/jj-on-the-hook-for-302m-in-pelvic-mesh-dispute/

Trending

Johnson & Johnson

Login